Title
Price, pricing and reimbursment of medicinal products in Bulgaria
Poster
Description
Dayana Marinova, Teodora Todorova, Mihaela Tuzharova
Faculty of Chemistry and Pharmacy, University of Sofia “St. Kliment Ohridski”
Faculty of Chemistry and Pharmacy, University of Sofia “St. Kliment Ohridski”
Subject
Establishing a system of norms and rules for pricing and reimbursement of medicinal products is an important part of the drug policy of a country. Creating lists of essential medicines – positive drug lists (PDL), helps regulating the use of medicinal products, prevents the use of ineffective medicines and minimizes the costs. The competent authority in regard to pricing and reimbursement of medicinal products in Bulgaria is the National Council of Prices and Reimbursement of Medicinal Products. The marketing authorization holders (MAH) of the medicinal products submit an application to The Council for inclusion in the positive drug list or for formation of ceiling or maximum sale prices. The Council then draws up a positive or negative opinion and informs the MAH.
In 2002 in Bulgaria was established “Positive Drug List”, but despite the passed years, there is no effective system, which can provide the population with enough medicinal products. There have been many changes in the rules and procedures without carrying out impact assessments, pharmacoeconomics and health-economics analyzes. Today many patients may be left without a treatment just because of this. This justifies applying urgent measures for the rational use of medicinal products and a strict monitoring of the necessary amounts of the medicines, in order to avoid leaving a patient with no treatment.
In 2002 in Bulgaria was established “Positive Drug List”, but despite the passed years, there is no effective system, which can provide the population with enough medicinal products. There have been many changes in the rules and procedures without carrying out impact assessments, pharmacoeconomics and health-economics analyzes. Today many patients may be left without a treatment just because of this. This justifies applying urgent measures for the rational use of medicinal products and a strict monitoring of the necessary amounts of the medicines, in order to avoid leaving a patient with no treatment.